Menopause and disorders of the central nervous system

Minerva Ginecologica

Volumn 57, Issue 6, 2005, Pages 579-592

  Henderson, V W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Critical window; Dementia; Estrogens; Hormone replacement therapy; Memory; Menopause; Mild cognitive impairment; Parkinson's disease; Stroke

Indexed keywords

ESTROGEN;

ALZHEIMER DISEASE; AMNESIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; ESTROGEN SYNTHESIS; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; NEUROLOGIC DISEASE; PARKINSON DISEASE; POSTMENOPAUSE; REVIEW; RISK REDUCTION;

AGED; ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MEMORY DISORDERS; MENOPAUSE; MIDDLE AGED;

EID: 29444434719     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. McCarthy MM, Konkle AT. When is a sex difference not a sex difference? Front Neuroendocrinol 2005;26:85-102.
2. Henderson VW. Hormone Therapy and the Brain: A Clinical Perspective on the Role of Estrogen. New York: Parthenon Publishing; 2000.
3. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J Comp Neurol 1997;388:507-25.
4. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 2005;67:335-76.
5. Foy MR, Henderson VW, Berger TW, Thompson RF. Estrogen and neural plasticity. Curr Dir Psychol Sci 2000;9:148-52.
6. Garcia-Segura LM, Cardona-Gomez P, Naftolin F, Chowen JA. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport 1998;9:593-7.
7. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 1996;66:1836-44.
8. Behl C, Skutella T, Lezoualch F, Post A, Widmann M, Newton CJ et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997;51:535-41.
9. Burger HG, Dudley EC, Hooper JL, Groome N, Guthrie JR, Green A et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025-30.
10. Squire LT, Zola-Morgan S. The medial temporal lobe memory system. Science 1991;253:1380-6.
11. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92.
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
13. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
14. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol 1993;336:293-306.
15. Bartus RT, Dean RL, Beer B, Lippa AD. The cholinergic hypothesis of geriatric memory dysfunction. Science 1981;217:208-17.
16. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 2003;41:268-87.
17. Shughrue PJ, Scrimo PJ, Merchenthaler I. Evidence for the colocalization of estrogen receptor-beta mRNA and estrogen receptor-alpha immunoreactivity in neurons of the rat forebrain. Endocrinology 1998;139:5267-70.
18. Luine V. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985;89:484-90.
19. Gibbs RB. Basal forebrain cholinergic neurons are necessary for estrogen to enhance acquisition of a delayed matching-to-position T-maze task. Horm Behav 2002;42:245-57.
20. Rapp PR, Morrison JH, Roberts JA. Cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys. J Neurosci 2003;23:5708-14.
21. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med 1994;154:2349-55.
22. Mitchell ES, Woods NF. Midlife women's attributions about perceived memory changes: observations from the Seattle Midlife Women's Health Study. J Womens Health Gender-Based Med 2001;10:351-62.
23. Woods NF, Mitchell ES, Adams C. Memory functioning among midlife women: observations from the Seattle Midlife Women's Health Study. Menopause 2000;7:257-65.
24. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.
25. Henderson VW, Dudley EC, Guthrie JR, Burger HG, Dennerstein L. Estrogen exposures and memory at midlife: a population-based study of women. Neurology 2003;60:1369-71.
26. Meyer PM, Powell LH, Wilson RS, Everson-Rose SA, Kravitz HM, Luborsky JL et al. A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology 2003;61:801-6.
27. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-57.
28. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-95.
29. Bagger YZ, Tankó LB, Alexandersen P, Qin G, Christiansen C. Early postmenopausal hormone replacement therapy may prevent cognitive impairment later in life. Menopause 2005;12:12-7.
30. Paganini-Hill A, Henderson VW. The effects of hormone replace therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc 1996;44:818-22.
31. Barrett-Connor E, Goodman-Gruen D. Cognitive function and endogenous sex hormones in older women. J Am Geriatr Soc 1999;47:1289-93.
32. Portin R, Polo-Kantola P, Polo O, Koskinen T, Revonsuo A, Irjala K et al. Serum estrogen level, attention, memory and other cognitive functions in middle-aged women. Climacteric 1999;2:115-23.
33. Drake EB, Henderson VW, Stanczyk FZ, McCleary CA, Brown WS, Smith CA et al. Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology 2000;54:599-603.
34. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology 1997;49:1491-7.
35. Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50:368-73.
36. Rice MM, Graves AB, McCurry SM, Gibbons LE, Bowen JD, McCormick WC et al. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: the Kame Project. Arch Intern Med 2000;160:1641-9.
37. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000;54:1949-53.
38. Carlson MC, Zandi PP, Plassman BL, Tschanz JT, Welsh-Bohmer KA, Steffens DC et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County study. Neurology 2001;57:2210-6.
39. Maki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry 2001;158:227-33.
40. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-41.
41. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc 1999;47:518-23.
42. Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 2004;63:101-7.
43. Shaywitz SE, Naftolin F, Zelterman D, Marchione KE, Holahan JM, Palter SF et al. Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen. Menopause 2003;10:420-6.
44. Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM. Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas 2001;38:137-46.
45. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med 2002;113:543-8.
46. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-68.
47. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003;2:43-53.
48. Wolf PA, D'Agostino RB. Epidemiology of stroke. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM editors. Stroke: pathophysiology, diagnosis, and management. 3 ed. New York: Churchill Livingstone; 1998.p.3-28.
49. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
50. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
51. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80.
52. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
53. Ross R. Mechanisms of disease: atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
54. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199-208.
55. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002;64:749-74.
56. Westendorp ICD, Veld BA, Bots ML, Akkerhuis JM, Hofman A, Gorbbee DE et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. Stroke 1999;30:2562-7.
57. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
58. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9.
59. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-8.
60. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45.
61. Alkayed NJ, Goto S, Sugo N, Joh HD, Klaus J, Crain BJ et al. Estrogen and Bcl-2: gene induction and effect of transgene in experimental stroke. J Neurosci 2001;21:7543-50.
62. Rau SW, Dubal DB, Bottner M, Gerhold LM, Wise PM. Estradiol attenuates programmed cell death after stroke-like injury. J Neurosci 2003;23:11420-6.
63. Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis 1995;38:223-42.
64. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
65. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS). Circulation 2001;103:638-42.
66. Viscoli CM, Brass LM, Kernan WN, Sarrel SM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
67. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84.
68. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-501.
69. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2003;55:1358-63.
70. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
71. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-86.
72. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93.
73. Morris HR. Genetics of Parkinson's disease. Ann Med 2005;37:86-96.
74. Roy EJ, Buyer DR, Licari VA. Estradiol in the striatum: effects on behavior and dopamine receptors but no evidence for membrane steroid receptors. Brain Res Bull 1990;25:221-7.
75. Beyer C, Ivanova T, Karolczak M, Kuppers E. Cell type-specificity of nonclassical estrogen signaling in the developing midbrain. J Steroid Biochem Mol Biol 2002;81:319-25.
76. Leranth C, Roth RH, Elswoth JD, Naftolin F, Horvath TL, Redmond DE Jr. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000;20:8604-9.
77. Sawada H, Shimohama S. Estrogens and Parkinson disease: novel approach for neuroprotection. Endocrine 2003;21:77-9.
78. Callier S, Morissett M, Grandbois M, Di Paolo T. Stereospecific prevention by 17β-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000;37:245-51.
79. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Research 1997;767:340-4.
80. Marder K, Tang M-X, Alfaro B, Mejia H, Cote L, Jacobs D et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998;50:1141-3.
81. Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-7.
82. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886-8.
83. Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology 2000;55:1572-4.
84. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999;52:1417-21.
85. Tsang K-L, Ho S-L, Lo S-K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000;54:2292-8.
86. Blanchet PJ, Fang F, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999;53:91-5.
87. Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids in Parkinson's disease in postmenopausal women. Clin Neuropharmacol 1999;22:93-7.
88. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. Neurology 1999;52:78-84.
89. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22.
90. Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997;48:132-8.
91. Kokmen E, Beard CM, O'Brien PC, Kurland LT. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 1996;71:275-82.
92. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
93. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. The preclinical phase of Alzheimer's disease: a 22-year prospective study of the Framingham cohort. Arch Neurol 2000;57:808-13.
94. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-9.
95. Bird TD. Genetic factors in Alzheimer's disease. N Engl J Med 2005;352:862-4.
96. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17:525-30.
97. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 1997;278:1349-56.
98. Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord 1999;13:216-21.
99. Shughrue PJ, Scrimo PJ, Merchenthaler I. Estrogen binding and estrogen receptor characterization (ERa and ERb) in the cholinergic neurons of the rat basal forebrain. Neuroscience 2000;96:41-9.
100. Petanceska SS, Nagy G, Frail D, Gandy S. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid b peptides in brain. Neurology 2000;54:2212-7.
101. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol 1997;143:313-8.
102. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE. Increased synaptic spouting in response to estrogen via an apolipoprotein E dependent mechanism: implications for Alzheimer's disease. J Neurosci 1998;18:3180-5.
103. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol Brain Res 1995;33:174-8.
104. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-22.
105. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002;22:201-10.
106. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
107. Jellinger KA, Attems J. Incidence of cerebrovascular lesions in Alzheimer's disease: a post mortem study. Acta Neuropathol (Berl) 2002;105:14-7.
108. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001;57:605-12.
109. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
110. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA 2000;283:1007-15.
111. Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061-6.
112. Rigaud AS, Andre G, Vellas B, Touchon J, Pere JJ. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 2003;60:148-9.
113. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. JAMA 1998;279:688-95.
114. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. Neuroscience 2000;101:485-512.
115. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study (WHIMS). JAMA 2003;289:2651-62.
116. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-58.
117. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Bäck-man L. The course of cognitive impairment in preclinical Alzheimer disease. Arch Neurol 2000;57:839-44.
118. Derby CA, Hume AL, Barbour MM, McPhillips JB, Lasater TM, Carleton RA. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol 1993;137:1125-35.
119. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8.
120. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med 1996;156:2213-7.
121. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudi-nal Study of Aging. Neurology 1997;48:1517-21.
122. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC et al. Hormone replacement therapy and incidence of Alzheimer's disease on older women: the Cache County study. JAMA 2002;288:2123-9.
123. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner R, Manson JE et al. The effect of estrogen with progestin treatment on global cognitive function in postmenopausal women: results from the Women's Health Initiative Memory Study. JAMA 2003;289:2663-72.
124. Savonenko AV, Markowska AL. The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Neuroscience 2003;119:821-30.
125. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 2002;288:2170-2.
126. Toran-Allerand CD. Estrogen as treatment for Alzheimer disease. JAMA 2000;284:307-8.
127. Gibbs RB. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging 2000;21:107-16.
128. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103-5.
129. Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-7.
130. Seshadri S, Zomberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. Arch Neurol 2001;58:435-40.